Investors should monitor upcoming IND filings for SC451 and first-in-human data from SG293 trials as key catalysts; the extended cash runway into late 2026 reduces near-term dilution risk despite no revenue
Price Chart
Executive Summary
Sana Biotechnology reported Q4 and full-year 2025 financial results alongside significant clinical and operational progress, including 12-month data from its UP421 type 1 diabetes study showing survival and function of hypoimmune-modified islet cells without immunosuppression, publication in NEJM, advancement of SC451 and SG293 programs toward clinical trials, and a strengthened cash position of $138.4 million providing runway into late 2026 following $133.7 million in equity raises.
Key Financial Metrics
Key Facts
- 12-month clinical data from UP421 study show hypoimmune-modified islet cells survive, function, and evade immune detection without immunosuppression in a type 1 diabetes patient
- NEJM published 12-week results and an accompanying editorial, validating scientific significance
- SC451 (iPSC-derived hypoimmune islet therapy) on track for IND filing and Phase 1 start as early as 2026
- SG293 (in vivo CAR-T fusosome) expected to generate first-in-human data in blood cancers in 2026
- Raised $133.7 million via ATM and public offering in 2025; cash position at $138.4 million as of Dec 31, 2025
- Non-GAAP net loss improved to $170.1 million in 2025 from $263.1 million in 2024 due to R&D prioritization and cost reductions
- Appointed new CFO, Brian Piper, in Q1 2026
Financial Impact
Reduced cash burn from $195.1M in 2024 to $138.5M in 2025 (Non-GAAP); $133.7M raised in equity financing offsets operating losses
Risk Factors
- Clinical development risks in early-stage programs (SC451, SG293)
- Heavy reliance on successful translation of preclinical/early clinical data into later-stage efficacy
- Future financing needs beyond late 2026 could lead to dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3248908 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $3.79 $3.17 | ▼ −16.36% | ▼ −15.30% | $2.90 (−23.35%) |
Aug 10, 2026 7w ago | Press Release | $3.79 $3.17 | ▼ −16.36% | ▼ −15.30% | $2.90 (−23.35%) |
May 11, 2026 20w ago | 8-K | $3.26 $2.82 | ▼ −13.50% | ▼ −11.77% | $2.90 (−10.89%) |
May 11, 2026 20w ago | Press Release | $3.26 $2.82 | ▲ +13.50% | ▲ +11.77% | $2.90 (+10.89%) |
Apr 24, 2026 23w ago | DEFA14A | $3.29 $3.15 | ▼ −4.26% | ▼ −8.28% | $2.90 (−11.70%) |
Apr 24, 2026 23w ago | 8-K | $3.29 $3.15 | ▼ −4.26% | ▼ −8.28% | $2.90 (−11.70%) |
Apr 13, 2026 24w ago | 8-K | $3.48 $3.56 | ▲ +2.30% | ▼ −4.00% | $2.90 (−16.52%) |
Apr 13, 2026 24w ago | Press Release | $3.48 $3.56 | ▲ +2.30% | ▼ −4.00% | $2.90 (−16.52%) |
Mar 13, 2026 29w ago | Press Release | $3.36 $3.21 | ▼ −4.46% | ▼ −8.05% | $2.90 (−13.54%) |
Mar 3, 2026 30w ago | Press Release | $3.82 $3.05 | ▼ −20.16% | ▼ −15.74% | $2.90 (−23.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access